5PSQ-094 Efficacy of basiliximab versus thymoglobulin in renal transplant induction therapy

<h3>Background and Importance</h3> Basiliximab (anti CD-25) and thymoglobulin (T-lymphocyte depleting agent) are used together with other immunosuppressants in renal transplant induction therapy for the prevention of acute rejection. The selection of the appropriate induction regimen, depending on the patient’s immunological risk, is key to ensure the success of the transplantation. <h3>Aim and Objectives</h3> To evaluate the efficacy of protocolised induction immunosuppressive therapy with basiliximab and thymoglobulin in renal transplantation. <h3>Material and Methods</h3> Retrospective and descriptive observational study carried out on patients transplanted during 01/2012 - 09/2023 in a tertiary general hospital. Patients, according to the protocol established in the centre, were treated with basiliximab or thymoglobulin in case of low or high immunological risk, respectively. The analysed variables were obtained from the Orion Clinic software: sex, age, weight, date of transplant, immunosuppressor used in conjunction with the dose administered: basiliximab 20mg on days +1 and +4 post-transplant and thymoglobulin 5 mg/kg/total cumulative dose for 3 to 9 days after the intervention, and concomitant immunosuppressive treatment. The effectiveness was evaluated by the rejection rates at 6 and 12 months after the transplantation, according to the literature reviewed. <h3>Results</h3> During the evaluated period, a total of 260 patients were transplanted: 65% men (169) and 35% women (91), with a mean age of 57 ±11.90 years. In addition, all patients were also treated with mycophenolate mofetil, prednisone and tacrolimus. Of these, 41.15% (107) of patients received basiliximab according to procotol, and 58.85% (153) of patients received thymoglobulin with a total cumulative mean dose of 6.1mg/kg. Among these 153 patients treated with thymoglobulin, 22.22% received &lt;5mg/kg due to haematological toxicity. Regarding to the rejection rates, 14.01% (15) and 0.93% (1) experienced rejection among the group of basiliximab after 6 and 12 months, respectively. While 12.42% (19) and 0.65% (1) experienced rejection among the group of thymoglobulin after 6 and 12 months, respectively, of which only two patients received doses &lt;5mg/kg because of toxicity. <h3>Conclusion and Relevance</h3> In our study population, basiliximab induction therapy in patients at low immunological risk was similarly effective as thymoglobulin therapy in patients at high immunological risk in renal transplantation, along with all other immunosuppressants, according to the literature reviewed. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest